Skip to main content

Table 1 Calculated parameters for the ability of the GEPR to predict disease control

From: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Parameter

KRAS-wildtype

All patients

KRAS-mutant

Specificity

0.32

0.4

0.5

Sensitivity

0.85

0.8

1

PPV

0.57

0.43

0.18

NPV

0.66

0.77

1

  1. NPV: negative predictive value; PPV positive predictive value
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us